Редактирование: CRABP2

Cellular retinoic acid-binding protein 2 (Cellular retinoic acid-binding protein II) (CRABP-II)

==Publications==

{{medline-entry
|title=Preconception resveratrol intake against infertility: Friend or foe?
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32273814
|abstract=Resveratrol is an antiaging, antioxidant, anti-inflammatory, and insulin-sensitizing natural polyphenolic compound. Growing evidence indicates that resveratrol has potential therapeutic effects in infertile women with diminished ovarian function, polycystic ovary syndrome (PCOS), or endometriosis. However, only one clinical trial in women undergoing in vitro fertilization (IVF) cycles using resveratrol has ever been reported. This review focuses on the potential therapeutic effects of resveratrol on pregnancy and on its advantages and disadvantages in pregnancy outcomes during infertility treatment. We performed a literature review to describe the known impacts of resveratrol on the ovary and endometrium. Resveratrol upregulates sirtuin (SIRT)1 expression in ovaries, which is associated with protection against oxidative stress. It leads to the activation of telomerase activity and mitochondrial function, improving ovarian function. In the endometrium, resveratrol downregulates the [[CRABP2]]-RAR pathway leading to suppressing decidual and senescent changes of endometrial cells, which is essential for embryo implantation and placentation. Moreover, resveratrol may also induce deacetylation of important decidual-related genes. Resveratrol has potential therapeutic effects for improving ovarian function; however, it also has anti-deciduogenic actions in uterine endometrium. In addition, its teratogenicity has not yet been ruled out; thus, resveratrol should be avoided during the luteal phase and pregnancy.

|keywords=* aging
* assisted reproductive technology
* infertility
* resveratrol
* sirtuin
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138940
}}
{{medline-entry
|title=Cross platform analysis of transcriptomic data identifies ageing has distinct and opposite effects on tendon in males and females.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29089527
|abstract=The development of tendinopathy is influenced by a variety of factors including age, gender, sex hormones and diabetes status. Cross platform comparative analysis of transcriptomic data elucidated the connections between these entities in the context of ageing. Tissue-engineered tendons differentiated from bone marrow derived mesenchymal stem cells from young (20-24 years) and old (54-70 years) donors were assayed using ribonucleic acid sequencing (RNA-seq). Extension of the experiment to microarray and RNA-seq data from tendon identified gender specific gene expression changes highlighting disparity with existing literature and published pathways. Separation of RNA-seq data by sex revealed underlying negative binomial distributions which increased statistical power. Sex specific de novo transcriptome assemblies generated fewer larger transcripts that contained miRNAs, lincRNAs and snoRNAs. The results identify that in old males decreased expression of [[CRABP2]] leads to cell proliferation, whereas in old females it leads to cellular senescence. In conjunction with existing literature the results explain gender disparity in the development and types of degenerative diseases as well as highlighting a wide range of considerations for the analysis of transcriptomic data. Wider implications are that degenerative diseases may need to be treated differently in males and females because alternative mechanisms may be involved.
|mesh-terms=* Aged
* Aging
* Cell Differentiation
* Cell Proliferation
* Female
* Gene Expression Profiling
* Humans
* Male
* Mesenchymal Stem Cells
* MicroRNAs
* Middle Aged
* RNA, Long Noncoding
* RNA, Small Nucleolar
* Receptors, Retinoic Acid
* Sequence Analysis, RNA
* Sex Characteristics
* Tendons
* Transcriptome
* Young Adult

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663855
}}